Cure8 research brief
Patients and clinicians choosing a next biologic after prior biologic failure may find evidence here that effectiveness is broadly similar between vedolizumab and ustekinumab overall, with potential differences depending on how many prior biologics a patient received.
Adult patients with ulcerative colitis who have previously used biologic therapy; clinicians deciding on subsequent biologic sequencing; researchers studying real-world biologic effectiveness.
This real-world analysis pooled data from 420 biologic-experienced UC patients treated between 2020–2024 across 14 centers. Primary outcomes were clinical remission and steroid-free clinical remission at weeks 14–16, 52, and 104, using statistical weighting to adjust baseline differences.
At group level the two drugs had similar rates of steroid-free clinical remission at most timepoints. At week 104 vedolizumab showed a higher clinical remission rate but without a corresponding difference in steroid-free remission, and the authors advise cautious interpretation because of limits in long-term follow-up.
In exploratory subgroup analyses, vedolizumab appeared more favorable in patients with a single prior biologic, while ustekinumab showed better outcomes in patients with two or more prior biologics; ustekinumab also had higher treatment persistence. Safety profiles were reported as comparable between treatments.
This is a retrospective, observational multicenter study (not a randomized trial). Subgroup analyses were exploratory and long-term (104-week) findings have limitations related to follow-up and potential residual confounding despite weighting adjustments.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative...
New trial and real-world data about Skyrizi and Rinvoq could affect treatment options and conversations about long-term outcomes for people with Crohn’s disease or ulcerative colitis. Investors’ coverage can increase...
This large real-world study found upadacitinib was associated with lower risk of treatment failure and more corticosteroid-free stability compared with several other advanced therapies for ulcerative colitis —...
